Preclinical assessment of anti-cancer drugs by using RP215 monoclonal antibody

Cancer Biology and Therapy

Volumn 8, Issue 2, 2009, Pages 161-166

  Lee, Gregory ^a   Chu, Rui Ai ^b   Ting, Hong Hoi ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

CA215; Immunohistochemistry; Nude mouse experiment; Pan cancer marker; Preclinical study

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC MONOCLONAL ANTIBODY RP 215; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RP 215; RECOMBINANT ANTIBODY; RP 215; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER TISSUE; COLON CANCER; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; LOW DRUG DOSE; LUNG CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; OVARY CANCER; STOMACH CANCER; TUMOR VOLUME; UTERINE CERVIX CANCER;

EID: 58749083934     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.2.7117     Document Type: Article

References (22)

1. Lee CYG, Chen KW, Sheu FS, Tsang A, Chao KC, Ng HT. Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody. Cancer Immunol Immunother 1992; 35:19-26.
2. Lee CYG, Ng HT. Clinical evaluation of a new ovarian cancer marker, COX-1. Int J Gynecol Obstet 1995; 27:49.
3. Lee G, Wu Q, Li C-H, Ting H-H, Chien, CH. Recent studies of a new carbohydrate-associated pan cancer marker, CA215. J Clin Ligand Assay 2006; 29:47-51.
4. Lee G, Laflamme E, Chien C-H, Ting HH. Molecular identity of a pan cancer marker, CA215. Cancer Biology and Therapy. In press.
5. Lee G. Monoclonal antibodies against an antigen associated with ovarian cervical and other tumors. United States Patent 5650291. 1997.
6. Bullock GR, Petrusz P, editors. Techniques in immunocytochemistry. Volume 1, Academic Press 1984.
7. Fogh J, Giovanella BC, editors. The Nude Mouse in Experimental and Clinical Research. Volume 1, Academic Press 1978.
8. Fogh J, Giovanella BC, editors. The Nude Mouse in Experimental and Clinical Research. Volume 2, Academic Press 1982.
9. Jones ST, Bending MM. Rapid PCR-cloning of full length mouse immunoglobulin variable regions. Bio Tech 1991; 9:88-9.
10. Shimoda M, Nakamura T, Takahashi Y, et al. Isotype-specific selection of high affinity memory B cells in nasal-associated lymphoid tissue. J Exp Med 2001; 194:1597-607.
11. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric antibody molecules: Mouse antigen binding domains with human constant region domains. PNAS 1984; 81:6851-5.
12. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementary-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-5.
13. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimeric mouse/human antibody. Nature 1984; 312:643-36.
14. Courtenay-Luck NS. Genetic manipulation of monoclonal antibodies. In Monoclonal antibodies-production, engineering and clinical application. Ritter M, Ladyman H, editors. Cambridge: Cambridge University Press 1995.
15. Xing JL, Yang XM, Zhang SH, Yao XY, Liang RA, Chen ZN. Construction of a universal expression vector for human-mouse chimeric Fab antibody and expression of chimeric Fab antibody against human hepatoma associated antigen Hab18G. World Chin J Digestol 2004; 12:271-5.
16. Yang XM, Xing JL, Liao CG, Yao XY, Li Y, Chen ZN. High efficiency reconstitution of a human-mouse chimeric Fab of Cab-1 antibody specific to human colon cancer. Scandinavian J of Immunol 2008; 68:12-21.
17. Adam GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotech 2005; 23:1147-57.
18. Blumenthal RD, Osorio L, Hayes MK, Horak ID, Hansen HJ, Goldenberg DM. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother 2005; 54:315-27.
19. DiGaetano, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171:1581-7.
20. Trikha M, Yan L, Nakada MT, Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 2002; 13:609-14.
21. Eccles SA. Monoclonal antibodies targeting cancer: "magic bullet" or just the trigger? Breast Cancer Research 2001; 3:86-90.
22. Berger M, Shanken V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci 2002; 324:14-30.